buy qualiti price color
affect biotech adjust pt
model updat manag color go
guidanc fell short run-rate management telegraph price
competit headwind howev note leader
commerci asset weather price pressur
know grow volum price believ may
read-through compani remain buy given stabl biz
non-legaci portfolio grow two phase catalyst
omemcativ phase tezepelumab asthma updat
model result guidanc adjust pt
appli full otezla sale run-rate impli
howev revenu guidanc fall short
impli run-rate note good guid street
often beat guidanc see chart despit price pressur
believ grow top-line volum growth pipelin execut
also note two phase asset data readout meaning
opportun provid addit dcf
report result revenu guidanc fell
short top-line growth expect manag guid street
price competit dynam expect maintain buy
adjust pt report top-line
revenu vs con ep
vs con revenu guidanc ep
tr target
vs con sale ep updat model reflect
result guidanc
guidanc impli flat growth base biz exclud otezla investor
like focus price competit headwind reiter buy rate highlight
stabl base biz otezla growth key late stage readout believ color provid
manag downward price pressur competit like caus greater concern
investor new pt reflect model updat result competition/
price dynam affect base busi compani guidanc well management color
guidanc continu convict behind abil grow non-legaci portfolio
geograph expans asia sizeabl market penetr could contribut top-line
growth deep pipelin execut multipl readout includ novel earlier stage asset
manag good guid street give commentari quarterli trend
respect price dynam script volum impact annual contract payer
note investor concern around manag color reiter buy rate stock
expect base biz stabl yoy believ price declin could potenti
off-set volum growth expect otezla growth continu contribut top-line
see multipl stock move key catalyst next month includ key readout phase
omecamtiv mecarbil heart failur phase tezepelumab
biosimilar competit could bring downward price pressur talk manag also
learn anyth biosimilar impact price compani note re-negoti price
give price battl competit abl hold onpro market
share despit two biosimilar market manag note lower price
neulasta subsequ onpro follow entri sandoz privat neulasta biosimilar
market ex-u biosimilar blind tender winner take nordic countri
exampl result manag note declin global expect
experi low-to-middle-singl digit declin global howev manag
note expect continu volum base growth despit neg impact price
biosimilar player market know play nice sandbox
payer react multipl biosimilar avail
biosimilar beat expect key contributor growth caveat contract process
add layer uncertainti report ww revenu biosimilar kajinti mvasi
amgevita versu consensu run-rate impli biosimilar
sale alreadi launch product addit biosimilar launch expect
biosimilar busi grow contribut top-line in-lin expect see
initi talk manag learn key factor competit
uncertainti biosimilar revenu stream contract simpl term everi contract
compani establish biosimilar entri new entrant landscap neg impact
contract view investor need reset view around biosimilar contract model
ww biosimilar revenu
grow volum product biosimilar pressur aimovig
repatha contract come place health corpor buy macdonald contract
allow gain access patient give room grow aimovig price
come grow top-line gain market share anoth exampl volum growth
penetr market asia even japan adopt rate launch ramp
impress age popul take prescript serious follow beigen
deal take time revenu come china product like kyproli blincyto
formulari see revenu trajectori take time develop good histori
page
figur million dollar except per share data
strh research compani report updat
page
incom product includ product contract/royalti oper oper itemsnet interest incom incom exc spec provis rate net ep per dilut s/o use adjust inc
figur million dollar except per share data
strh research compani report updat
page
balanc asset equival market current current liabilitiesaccount portion current note carri term non-curr stock earn liabil compani report strh estim amgen inc
figur million dollar except per share data
strh research compani report updat
page
flow oper net incom gaap non-oper item depreci base non- benefit stock account current rev/oth chang flow invest capit market flow financingstock issuanc compani report strh estim amgen inc
figur million dollar except per share data
strh research compani report updat
page
million except per share free projectionsgaap ebit multipli tax tax stock base depreci less work capit less capit oper free valu non-gaap net incom return valu growth rate valu valu outstand valu per valu per compani report strh inc
inc biotechnolog compani engag discoveri develop
manufactur market human therapeut product includ follow brand aranesp
parsabiv prolia repatha sensipar vectibix xgeva compani found william
bow jr franklin pitcher johnson jr georg rathmann joseph rubinfeld april
headquart thousand oak ca
tough tape ahead elect believ provid predict earn
histori beat estim quarterli specialti drive growth product mid-way
life cycl see stabil growth potenti upsid product includ biosimilar
aimovig even otezla repatha think street underestim abil grow
new product biosimilar come market non-legaci product grow believ
street need pipelin success true growth see upsid await signific late-
stage data readout tezepleumab see earli pipelin data readout
rate share buy
valuat risk
target price deriv dcf assum legaci sale declin
non-legaci peak sale adjust pipelin sale
use discount rate appropri lower risk biotech use higher termin valu vs
model beyond patent cliff believ use capit product
risk rate price target includ on-going generic/biosimilar competit part price
pressur poorer expect sale pipelin failur
compani mention note
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
